Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0VALSS
ADC Name
HER2 KSP-ADC 1.4
Synonyms
HER2-KSP-ADC-1.4
   Click to Show/Hide
Drug Status
Investigative
Indication
In total 1 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Investigative
Drug-to-Antibody Ratio
3.6
Antibody Name
BAY-865
  Antibody Info 
Antigen Name
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
  Antigen Info 
Payload Name
Pyrrole based kinesin spindle protein inhibitor
  Payload Info 
Therapeutic Target
Kinesin-like protein KIF11 (KIF11)
  Target Info 
Linker Name
Kinesin spindle protein inhibitor (KSPi)-ADC linker 4
  Linker Info 
Conjugate Type
Random conjugation through reduced inter-chain cysteines.
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
0.2
nM
KPL-4 cells
Breast inflammatory carcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.20 nM Positive HER2 expression (HER2 +++/++)
Method Description
Drug-to-antibody ratios (DARs) and potency of the ADCs in the HER-2 positive breast cancer cell line KPL-4.
In Vitro Model Breast inflammatory carcinoma KPL-4 cells CVCL_5310
References
Ref 1 Antibody-Drug Conjugates with Pyrrole-Based KSP Inhibitors as the Payload Class. Angew Chem Int Ed Engl. 2018 Nov 12;57(46):15243-15247. doi: 10.1002/anie.201807619. Epub 2018 Oct 15.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.